Drug Profile
GB 2064
Alternative Names: GB-2064; PAT 1251Latest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator PharmAkea Therapeutics
- Developer Galecto Inc
- Class Amines; Antifibrotics; Fluorinated hydrocarbons; Ketones; Phenyl ethers; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action LOXL2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myelofibrosis
- No development reported Hepatic fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 21 Dec 2023 Efficacy and adverse events data from a phase IIa MYLOX-1 trial in Myelofibrosis released by Galecto
- 08 Jun 2023 Adverse events and efficacy data from phase-II Mylox-1 trial in Myelofibrosis presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 10 Dec 2022 Interim adverse events and efficacy data from phase-II Mylox-1 trial in Myelofibrosis presented at the 64th Annual Meeting and Exposition of the American Society of Hematology